PBYI
Price
$3.33
Change
+$0.02 (+0.60%)
Updated
Jun 27 closing price
Capitalization
165.29M
31 days until earnings call
RGNX
Price
$8.39
Change
-$0.36 (-4.11%)
Updated
Jun 27 closing price
Capitalization
422.76M
30 days until earnings call
Interact to see
Advertisement

PBYI vs RGNX

Header iconPBYI vs RGNX Comparison
Open Charts PBYI vs RGNXBanner chart's image
Puma Biotechnology
Price$3.33
Change+$0.02 (+0.60%)
Volume$699.74K
Capitalization165.29M
REGENXBIO
Price$8.39
Change-$0.36 (-4.11%)
Volume$1.19M
Capitalization422.76M
PBYI vs RGNX Comparison Chart in %
Loading...
PBYI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PBYI vs. RGNX commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PBYI is a Buy and RGNX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (PBYI: $3.33 vs. RGNX: $8.39)
Brand notoriety: PBYI and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PBYI: 193% vs. RGNX: 103%
Market capitalization -- PBYI: $165.29M vs. RGNX: $422.76M
PBYI [@Biotechnology] is valued at $165.29M. RGNX’s [@Biotechnology] market capitalization is $422.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PBYI’s FA Score shows that 1 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • PBYI’s FA Score: 1 green, 4 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, PBYI is a better buy in the long-term than RGNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PBYI’s TA Score shows that 3 TA indicator(s) are bullish while RGNX’s TA Score has 4 bullish TA indicator(s).

  • PBYI’s TA Score: 3 bullish, 3 bearish.
  • RGNX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, PBYI is a better buy in the short-term than RGNX.

Price Growth

PBYI (@Biotechnology) experienced а +4.23% price change this week, while RGNX (@Biotechnology) price change was -0.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

PBYI is expected to report earnings on Jul 31, 2025.

RGNX is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGNX($423M) has a higher market cap than PBYI($165M). PBYI YTD gains are higher at: 9.180 vs. RGNX (8.538). PBYI has higher annual earnings (EBITDA): 54.7M vs. RGNX (-122.44M). RGNX has more cash in the bank: 268M vs. PBYI (93.2M). PBYI has less debt than RGNX: PBYI (61.7M) vs RGNX (79.8M). PBYI has higher revenues than RGNX: PBYI (233M) vs RGNX (157M).
PBYIRGNXPBYI / RGNX
Capitalization165M423M39%
EBITDA54.7M-122.44M-45%
Gain YTD9.1808.538108%
P/E Ratio4.27N/A-
Revenue233M157M148%
Total Cash93.2M268M35%
Total Debt61.7M79.8M77%
FUNDAMENTALS RATINGS
PBYI vs RGNX: Fundamental Ratings
PBYI
RGNX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
73
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
1997
PRICE GROWTH RATING
1..100
5357
P/E GROWTH RATING
1..100
9721
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PBYI's Valuation (37) in the Biotechnology industry is somewhat better than the same rating for RGNX (73). This means that PBYI’s stock grew somewhat faster than RGNX’s over the last 12 months.

PBYI's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RGNX (100). This means that PBYI’s stock grew similarly to RGNX’s over the last 12 months.

PBYI's SMR Rating (19) in the Biotechnology industry is significantly better than the same rating for RGNX (97). This means that PBYI’s stock grew significantly faster than RGNX’s over the last 12 months.

PBYI's Price Growth Rating (53) in the Biotechnology industry is in the same range as RGNX (57). This means that PBYI’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's P/E Growth Rating (21) in the Biotechnology industry is significantly better than the same rating for PBYI (97). This means that RGNX’s stock grew significantly faster than PBYI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PBYIRGNX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
83%
Momentum
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
87%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
87%
Advances
ODDS (%)
N/A
Bullish Trend 19 days ago
75%
Declines
ODDS (%)
Bearish Trend 10 days ago
86%
Bearish Trend 10 days ago
84%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
61%
View a ticker or compare two or three
Interact to see
Advertisement
PBYI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ASBFF27.88N/A
N/A
Associated British Foods plc
HRSEF105.81N/A
N/A
Hirose Electric
SOUTF0.04N/A
N/A
Southern Energy Corp.
CSGQF1.38N/A
N/A
Costain Group Plc
PMMCF0.12-0.01
-5.38%
Pampa Metals Corporation

PBYI and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBYI has been loosely correlated with AURA. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if PBYI jumps, then AURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBYI
1D Price
Change %
PBYI100%
+0.60%
AURA - PBYI
37%
Loosely correlated
-0.16%
ACIU - PBYI
37%
Loosely correlated
-2.90%
COGT - PBYI
37%
Loosely correlated
-3.14%
RGNX - PBYI
36%
Loosely correlated
-4.11%
VYGR - PBYI
35%
Loosely correlated
-0.34%
More

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with DNLI. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
-4.11%
DNLI - RGNX
58%
Loosely correlated
-2.69%
ARWR - RGNX
55%
Loosely correlated
+0.06%
BEAM - RGNX
53%
Loosely correlated
-1.98%
ARCT - RGNX
52%
Loosely correlated
-7.49%
VYGR - RGNX
51%
Loosely correlated
-0.34%
More